Subscribe

Lisa A. Raedler, PhD, RPh

Medical Writer

Authored Articles

Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination Approved for the Treatment of Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates, Lymphoma
2019 Fourth Annual Oncology Guide to New FDA Approvals
Read Article
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates, Ovarian Cancer
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates, Hematologic Malignancies, Leukemia
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
Bladder Cancer, FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates, Hematologic Malignancies, Multiple Myeloma
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh
Breast Cancer, FDA Approvals, News & Updates, Solid Tumors
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh
Bladder Cancer, FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates, Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates, Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates, Lung Cancer
2018 Third Annual Oncology Guide to New FDA Approvals
Read Article
Balancing Innovation and Value in Cancer Care: Spotlight on Non–Small-Cell Lung Cancer Treatment
Lisa A. Raedler, PhD, RPh
Lung Cancer, Value in Oncology
February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non–Small-Cell Lung Cancer Treatment
Read Article
Sustol First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV
Lisa A. Raedler, PhD, RPh
Drug Updates
November 2016, Vol 7, No 10
Read Article
Cabometyx (Cabozantinib) Tablets First Multikinase Inhibitor Approved for the Treatment of Patients with Advanced Renal-Cell Carcinoma
Lisa A. Raedler, PhD, RPh
Drug Updates
October 2016, Vol 7, No 9
Read Article
Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
Drug Updates, FDA Approvals, News & Updates
September 2016, Vol 7, No 8
Read Article
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
Drug Updates
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Drug Updates
May 2016, Vol 7, No 4
Read Article
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Drug Updates
April 2016, Vol 7, No 3
Read Article
Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh
Drug Updates
March 2016, Vol 7, No 2
Read Article
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh
Drug Updates
December 2015, Vol 6, No 11
Read Article
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
Drug Updates
August 2015, Vol 6, No 7
Read Article
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Drug Updates, Multiple Myeloma
July 2015, Vol 6, No 6
Read Article
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
Lisa A. Raedler, PhD, RPh
Drug Updates
June 2015, Vol 6, No 5
Read Article
Beleodaq (Belinostat) Receives FDA Approval for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Lisa A. Raedler, PhD, RPh
Drug Updates
October 2014, Vol 5 , No 8
Read Article
Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil
Lisa A. Raedler, PhD, RPh
Drug Updates
September 2014, Vol 5, No 7
Read Article
Zykadia (Ceritinib) Approved for the Treatment of Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh
Drug Updates
August 2014, Vol 5, No 6
Read Article
Imbruvica (Ibrutinib) the First Bruton’s Tyrosine Kinase Inhibitor Approved for Treatment of Patients with Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
Drug Updates
May 2014, Vol 5, No 4
Read Article
Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Lisa A. Raedler, PhD, RPh
Drug Updates
March 2014, Vol 5, No 2
Read Article
Abraxane Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh
Drug Updates
February 2014, Vol 5, No 1
Read Article
Gilotrif: Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation
Lisa A. Raedler, PhD, RPh
Drug Updates
November 2013, Vol 4, No 9
Read Article
Revlimid Receives a New Indication for the Treatment of Patients with Relapsed or Progressing Mantle-Cell Lymphoma
Lisa A. Raedler, PhD, RPh
Drug Updates
October 2013, Vol 4, No 8
Read Article
Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations
Lisa A. Raedler, PhD, RPh
Drug Updates
September 2013, Vol 4, No 7
Read Article
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
Drug Updates
July 2013, Vol 4, No 6
Read Article
Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
Drug Updates
June 2013, Vol 4, No 5
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

© Amplity Health. All Rights Reserved. Privacy Policy.